Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma

NACompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

February 28, 2021

Study Completion Date

February 10, 2021

Conditions
Pancreatic Adenocarcinoma
Interventions
OTHER

MRIs with and without intravenous contrast (up to 2)

Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis.

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

All Listed Sponsors
lead

Columbia University

OTHER

NCT02775786 - Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma | Biotech Hunter | Biotech Hunter